177 related articles for article (PubMed ID: 35782609)
41. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3.
Anurathapan U; Tim-Aroon T; Zhang W; Sanpote W; Wongrungsri S; Khunin N; Chutipongtanate S; Chirdkiatgumchai V; Ngiwsara L; Jaovisidha S; Khongkraparn A; Pakakasama S; Svasti J; Setchell KDR; Wattanasirichaigoon D; Hongeng S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30149. PubMed ID: 36562549
[TBL] [Abstract][Full Text] [Related]
43. Very rare condition of multiple Gaucheroma: A case report and review of the literature.
Tseng SY; Niu DM; Chu TH; Yeh YC; Huang MH; Yang TF; Liao HC; Chiang CC; Ho HC; Soong WJ; Yang CF
Mol Genet Metab Rep; 2019 Sep; 20():100489. PubMed ID: 31341788
[TBL] [Abstract][Full Text] [Related]
44. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
45. Very rare condition of multiple Gaucheroma: A case report and review of the literature.
Tseng SY; Niu DM; Chu TH; Yeh YC; Huang MH; Yang TF; Liao HC; Chiang CC; Ho HC; Soong WJ; Yang CF
Mol Genet Metab Rep; 2019 Sep; 20():100473. PubMed ID: 31193028
[TBL] [Abstract][Full Text] [Related]
46. A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.
Abrams R; Kaddi CD; Tao M; Leiser RJ; Simoni G; Reali F; Tolsma J; Jasper P; van Rijn Z; Li J; Niesner B; Barrett JS; Marchetti L; Peterschmitt MJ; Azer K; Neves-Zaph S
CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):374-383. PubMed ID: 32558397
[TBL] [Abstract][Full Text] [Related]
47. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.
Tylki-Szymańska A; Szymańska-Rożek P; Hasiński P; Ługowska A
Mol Genet Metab; 2018 Apr; 123(4):495-500. PubMed ID: 29530534
[TBL] [Abstract][Full Text] [Related]
48. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
[TBL] [Abstract][Full Text] [Related]
49. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
50. Gaucher disease.
Nagral A
J Clin Exp Hepatol; 2014 Mar; 4(1):37-50. PubMed ID: 25755533
[TBL] [Abstract][Full Text] [Related]
51. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
52. Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease.
Lipiński P; Szymańska-Rożek P; Socha P; Tylki-Szymańska A
Mol Genet Metab; 2020 Feb; 129(2):125-131. PubMed ID: 31704237
[TBL] [Abstract][Full Text] [Related]
53. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
54. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
[TBL] [Abstract][Full Text] [Related]
55. Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
Dinur T; Bauer P; Beetz C; Cozma C; Becker-Cohen M; Istaiti M; Rolfs A; Skrahina V; Zimran A; Revel-Vilk S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835356
[TBL] [Abstract][Full Text] [Related]
56. Metabolizing profile of the cytochrome pathway CYP2D6, CYP3A4 and the ABCB 1 transporter in Spanish patients affected by Gaucher disease.
Almeida-Calpe A; López de Frutos L; Medrano-Engay B; García-García CB; Ribate MP; Giraldo P
Chem Biol Interact; 2021 Aug; 345():109527. PubMed ID: 34058179
[TBL] [Abstract][Full Text] [Related]
57. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
[TBL] [Abstract][Full Text] [Related]
58. Long-term response in biochemical markers of bone turnover during enzyme replacement therapy in a case-series of patients with Gaucher disease type I from Northern Greece.
Vargiami E; Dimitriadou M; Economou M; Christoforidis A; Zafeiriou DI
Hippokratia; 2016; 20(2):153-159. PubMed ID: 28416913
[TBL] [Abstract][Full Text] [Related]
59. The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher Disease.
Torralba-Cabeza MÁ; Olivera-González S; Sierra-Monzón JL
Diseases; 2018 Jul; 6(3):. PubMed ID: 30049986
[TBL] [Abstract][Full Text] [Related]
60. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
